Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Suven-Pharmaceuticals"

24 News Found

CCI approves Berhyanda's acquisition of Suven Pharma
News | April 22, 2023

CCI approves Berhyanda's acquisition of Suven Pharma

The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.

Casper Pharma receives EIR from USFDA for its PAI
Drug Approval | October 05, 2022

Casper Pharma receives EIR from USFDA for its PAI

The inspection concluded with no observation (FDA-483) issued.

Casper Pharma completed USFDA pre-approval inspection
Drug Approval | July 31, 2022

Casper Pharma completed USFDA pre-approval inspection

The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore
News | February 08, 2022

Suven Pharma Q3FY22 PAT at Rs. 160.06 crore

Suven Pharmaceuticals has reported consolidated financial results for the period ended December 31, 2021.

Latest Stories

FDA approves Bayer’s Lynkuet as first hormone-free therapy for menopausal hot flashes

AskBio’s gene therapy shows promising 12-month results for heart failure

Elixion Biotech takes quantum-informed R&D route for next-gen precision medicines

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
India remains a very important part of our ecosystem: Vaios Barlas, Global Director Healthcare, Clariant and Bhushan Thekedar, Head of Global Business Development Healthcare, Clariant
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries

Packaging